Déjà vu? Galt's insomnia drug Doral gets 2nd wrist slap from FDA promo police

FDA Building 2
With its latest letter to Galt Pharmaceuticals, the FDA has now sent seven warnings to pharma marketers this year. (FDA)

It’s a repeat offense for sleep drug Doral. The FDA's ad watchdog, the Office of Prescription Drug Promotion (OPDP), slapped Galt Pharmaceuticals with a warning letter in September about an email it sent to physicians that omits serious drug risks.

It’s the second time OPDP has flagged Doral marketing. It previously sent an untitled letter in 2014 to then-Doral marketer Sciecure Pharma for a professional sales aid about missing risk information and material facts that had been omitted.

In the newest letter (PDF), OPDP expressed its concern about the recurrence, saying, “While Sciecure is no longer the application holder, OPDP is concerned that Galt is continuing to promote this product in a similarly violative manner.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Metuchen's 'misleading' ads for ED drug Stendra draw 2019's first FDA warning letter

The Doral warning letter is the second of the more serious category of "warning" letter for 2019, although five untitled letters have also been delivered. That brings the total pharma marketing violations to seven notched by the FDA so far this year.

The latest untitled letter (PDF), sent recently, dinged Kowa Pharmaceuticals for cholesterol fighter Livalo and a DTC patient testimonial video on its website the FDA said understates side effects. It also pointed out that the patient testimonials “compete for the viewers’ attention,” making it difficult to properly assess risks.

RELATED: FDA promo police spank Aclaris for misleading info in Eskata video

While OPDP letters to pharma companies have slowed in the past few years, September was busy by comparison with two letters sent. The seven letters so far in 2019 ties last year’s total. OPDP sent five letters in 2017, 11 in 2016 and nine in 2015.

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.